2OK Stock Overview
SpectraCure AB (publ) engages in the development of cancer treatment system.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SpectraCure AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.18 |
| 52 Week High | kr0.54 |
| 52 Week Low | kr0.15 |
| Beta | 0.71 |
| 1 Month Change | -10.39% |
| 3 Month Change | -36.00% |
| 1 Year Change | -52.62% |
| 3 Year Change | -81.09% |
| 5 Year Change | -88.80% |
| Change since IPO | -76.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2OK | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 18.0% | -5.4% | -2.5% |
| 1Y | -52.6% | -6.2% | -0.4% |
Return vs Industry: 2OK underperformed the German Medical Equipment industry which returned -6.2% over the past year.
Return vs Market: 2OK underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 2OK volatility | |
|---|---|
| 2OK Average Weekly Movement | 18.0% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2OK's share price has been volatile over the past 3 months.
Volatility Over Time: 2OK's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 15 | Masoud Khayyami | www.spectracure.com |
SpectraCure AB (publ) engages in the development of cancer treatment system. It develops Q-PRO, a laser device; and IDOSE software with interstitial photodynamic therapy system for the treatment of prostate cancer. The company was incorporated in 2003 and is based in Lund, Sweden.
SpectraCure AB (publ) Fundamentals Summary
| 2OK fundamental statistics | |
|---|---|
| Market cap | €19.72m |
| Earnings (TTM) | -€1.75m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.3x
P/E RatioIs 2OK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2OK income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | -kr9.54m |
| Gross Profit | kr9.54m |
| Other Expenses | kr29.98m |
| Earnings | -kr20.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2OK perform over the long term?
See historical performance and comparison